#POLB Poolbeg Pharma PLC – Favourable Conclusion of Patent Opposition September 29, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

29 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that further to its announcement on 19 September 2023, the oral opposition hearing scheduled by the European Patent Office (‘EPO’) relating to the challenge to the Company’s European patent (Immunomodulator I), has been cancelled. This favourably concludes this matter with the patent maintained as granted. The Immunomodulator I European patent was…

#HVO hVIVO Plc – Exercise of Options March 23, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, confirms that it has issued 7,716,964 new ordinary shares of 0.1 pence each in the capital of the Company (“Ordinary Shares”), pursuant to the exercise of share options by a former employee of the Company. It is expected that the admission of the Ordinary…

#POLB Poolbeg Pharma PLC – Positive Initial Data Analysis in POLB 001 Trial January 9, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

Key Highlights · POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo · A clear dose-response relationship was demonstrated · Well tolerated across all doses and no serious adverse events or volunteer withdrawals were reported · Full data read-out expected in Q2 2023 following a final quality check of the unblinded data 9 January 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or…

#ORPH Open Orphan plc – Positive in vitro results for FLU-v published September 30, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that positive data from a peer-reviewed study evaluating the in vitro efficacy of FLU-v, Imutex Limited’s (“Imutex”) broad spectrum influenza vaccine, has been published in the scientific journal Vaccines.1 Previous clinical studies have demonstrated that FLU-v induced increased…

#POLB Poolbeg Pharma – Confirmation of vaccine platform licence execution January 31, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

31 January, 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, confirms that it has signed the licence to AnaBio Technologies’ (‘AnaBio’) microencapsulation and nanoencapsulation technologies to develop an oral vaccine delivery platform. This follows the binding term sheet announced on 16 December 2021. This licence provides Poolbeg with exclusive access to AnaBio’s microencapsulation and nanoencapsulation technologies for use in the…

#POLB Poolbeg Pharma PLC – Favourable Conclusion of Patent Opposition September 29, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

#HVO hVIVO Plc – Exercise of Options March 23, 2023 – Posted in: hVIVO (HVO)

#POLB Poolbeg Pharma PLC – Positive Initial Data Analysis in POLB 001 Trial January 9, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

#ORPH Open Orphan plc – Positive in vitro results for FLU-v published September 30, 2022 – Posted in: Blog, Open Orphan (ORPH)

#POLB Poolbeg Pharma – Confirmation of vaccine platform licence execution January 31, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

Address

Contact

Social

LEGAL